Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CFTR2 | RCV001009446 | SCV001981574 | pathogenic | Cystic fibrosis | 2021-09-24 | reviewed by expert panel | research | |
Baylor Genetics | RCV001004479 | SCV001163524 | pathogenic | Cystic fibrosis; Congenital bilateral aplasia of vas deferens from CFTR mutation | criteria provided, single submitter | clinical testing | ||
CFTR- |
RCV001009446 | SCV001169497 | pathogenic | Cystic fibrosis | 2018-01-29 | criteria provided, single submitter | curation | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001009446 | SCV005077012 | pathogenic | Cystic fibrosis | 2024-04-23 | criteria provided, single submitter | clinical testing | Variant summary: CFTR c.2502dupT (p.Asp835X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which is a commonly known mechanism for disease. The variant was absent in 1613160 control chromosomes (gnomAD v4.1). c.2502dupT has been reported in the literature in individuals affected with Cystic Fibrosis (e.g. Soltysova_2017). The following publication has been ascertained in the context of this evaluation (PMID: 28544683). ClinVar contains an entry for this variant (Variation ID: 53503). Based on the evidence outlined above, the variant was classified as pathogenic. |
Natera, |
RCV001826639 | SCV002080759 | pathogenic | CFTR-related disorder | 2017-03-17 | no assertion criteria provided | clinical testing |